Pancreatic Cancer Research

ResearcherHumanitas UniversityActive in the last 2 years

Gennaro Nappo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6048-898X; OpenAlex author ID A5021454394, A5087753847. Sources: OpenAlex.

Their work

Papers
26 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
78
Papers, trials and grants by year

2014: 2 papers · 2015: 1 paper · 2016: none · 2017: 2 papers · 2018: none · 2019: none · 2020: 3 papers · 2021: 1 paper · 2022: 2 papers · 2023: 4 papers · 2024: 2 papers · 2025: 5 papers · 2026: 4 papers

Papers 26

  1. Pancreatic cancer surgery in Italy: an updated snapshot from a national multicentre analysis of outcomes by hospital volume. Co-author DOI 10.1007/s13304-026-02813-5↗
  2. Metabolomic profiling of pancreatic juice: a potential prognostic tool for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.suronc.2026.102456↗
  3. The TGF-βR1 inhibitor galunisertib re-shapes the PDAC-TME by limiting decidual-like natural killer cells polarization. Co-author DOI 10.1038/s41419-026-08581-9↗
  4. Futility in adenosquamous pancreatic cancer. Co-author DOI 10.1186/s12957-026-04351-1↗
  5. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  6. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  7. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  8. Carbohydrate antigens Lewis a and Lewis b act as tumor markers cooperating with CA19.9 in the management of PDAC patients. Co-author DOI 10.1016/j.cca.2024.119990↗
  9. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  10. Depicting the cellular complexity of pancreatic adenocarcinoma by Imaging Mass Cytometry: focus on cancer-associated fibroblasts. Co-author DOI 10.3389/fimmu.2024.1472433↗
  11. Integrating metabolic profiling of pancreatic juice with transcriptomic analysis of pancreatic cancer tissue identifies distinct clinical subgroups. Co-author DOI 10.3389/fonc.2024.1405612↗
  12. Pathologic tumor response to neoadjuvant therapy in resected pancreatic cancer: does it affect prognosis? First author DOI 10.1007/s13304-023-01628-y↗
  13. Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: A retrospective,… Co-author DOI 10.3389/fnut.2023.1065294↗
  14. Corrigendum: Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: a r… Co-author DOI 10.3389/fnut.2023.1212436↗
  15. Early Recurrence after Upfront Surgery for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/curroncol30040282↗
  16. Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival. Co-author DOI 10.1016/j.dld.2021.06.006↗
  17. Invasive IPMN relapse later and more often in lungs in comparison to pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2022.05.006↗
  18. Borderline resectable pancreatic cancer: Certainties and controversies. Co-author DOI 10.4240/wjgs.v13.i6.516↗
  19. Pancreatectomy With Arterial Resection for Pancreatic Adenocarcinoma: How Can It Be Done Safely and With Which Outcomes?: A Single Institution's Experience Wit… Co-author DOI 10.1097/sla.0000000000003010↗
  20. Metabolome of Pancreatic Juice Delineates Distinct Clinical Profiles of Pancreatic Cancer and Reveals a Link between Glucose Metabolism and PD-1+ Cells. Co-author DOI 10.1158/2326-6066.cir-19-0403↗
  21. Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma. Co-author DOI 10.3791/61687↗
  22. Prognostic value of venous invasion in resected T3 pancreatic adenocarcinoma: Depth of invasion matters. Co-author DOI 10.1016/j.surg.2017.03.008↗
  23. The borderline resectable/locally advanced pancreatic ductal adenocarcinoma: What should be the surgeon's choice? First author DOI 10.4103/eus.eus_69_17↗
  24. hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/bjc.2015.28↗
  25. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature. Co-author DOI 10.1016/j.pan.2014.07.002↗
  26. Reply to 'Hospital volume, margin status, and long-term survival after pancreaticoduodenectomy for pancreatic adenocarcinoma' (Am Surg 2012;78:225-9). First author DOI 10.1177/000313481408000130↗

Closest collaborators

The 25 strongest of 78 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alessandro Zerbi · 16 shared papers, 2017–2026 · strength 2.74
  2. Giovanni Luigi Capretti · 10 shared papers, 2020–2026 · strength 1.58
  3. Silvia Bozzarelli · 5 shared papers, 2022–2024 · strength 0.85
  4. Francesca Gavazzi · 5 shared papers, 2020–2026 · strength 0.83
  5. Greta Donisi · 5 shared papers, 2020–2023 · strength 0.79
  6. Marialuisa Barbagallo · 4 shared papers, 2020–2026 · strength 0.65
  7. Federica Marchesi · 4 shared papers, 2020–2026 · strength 0.65
  8. Pietro Addeo Md · 3 shared papers, 2017–2026 · strength 0.40
  9. Philippe Bachellier · 3 shared papers, 2017–2026 · strength 0.40
  10. Nina Cortese · 3 shared papers, 2020–2024 · strength 0.37
  11. Silvia Carrara · 2 shared papers, 2022 · strength 0.30
  12. Elena Desiato · 1 shared paper, 2026 · strength 0.28
  13. Matteo De Pastena · 2 shared papers, 2023 · strength 0.26
  14. Giuseppe Malleo · 2 shared papers, 2023 · strength 0.26
  15. Luca Vittorio Gianotti · 2 shared papers, 2023 · strength 0.26
  16. Darío Gregori · 2 shared papers, 2023 · strength 0.26
  17. Erica Secchettin · 2 shared papers, 2023 · strength 0.26
  18. Riccardo Casadei · 2 shared papers, 2023 · strength 0.26
  19. Carlo Ingaldi · 2 shared papers, 2023 · strength 0.26
  20. Marta Sandini · 2 shared papers, 2023 · strength 0.26
  21. Ilaria Trestini · 2 shared papers, 2023 · strength 0.26
  22. Giulia Angela Zamboni · 2 shared papers, 2023 · strength 0.26
  23. Laura Maggino · 2 shared papers, 2023 · strength 0.26
  24. Claudio Ricci · 2 shared papers, 2023 · strength 0.26
  25. Michèle Milella · 2 shared papers, 2023 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.